Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17437502 | 1.00 | IDO1 (0.35) | IDO1CACNA1HKMT2AMEN1TP53 | |
| SCHEMBL17437592 | 0.89 | CACNA1H (0.32) | CACNA1HKMT2AMEN1TP53MAPT | |
| SCHEMBL8873557 | 0.72 | ALDH1A1 (0.33) | KMT2AMEN1 | |
| SCHEMBL8874052 | 0.68 | ALDH1A1 (0.33) | KMT2AMEN1 | |
| SCHEMBL8874023 | 0.67 | CES2 (0.33) | CACNA1H | |
| SCHEMBL8873209 | 0.66 | CES2 (0.37) | CACNA1HKMT2AMAPT | |
| SCHEMBL9054976 | 0.64 | HDAC8 (0.39) | MAPT | |
| SCHEMBL8873705 | 0.64 | MAPT (0.36) | TP53MAPTSMN1; SMN2 | |
| SCHEMBL9402167 | 0.62 | TSHR (0.39) | IDO1KMT2AMEN1ADAMTS5 | |
| SCHEMBL8872301 | 0.61 | MAPT (0.35) | CACNA1HMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10208023-B2 | Heterocyclic inhibitors of the sodium channel | DeGiacomo, Mark G. (US) | 2019-02-19 | — | — | US | disclosed |
| US-20170107203-A1 | HETEROCYCLIC INHIBITORS OF THE SODIUM CHANNEL | EPIRUS BIOPHARMACEUTICALS, INC. (US) | 2017-04-20 | — | — | US | disclosed |
| US-20160016939-A1 | HETEROCYCLIC INHIBITORS OF THE SODIUM CHANNEL | NATIONAL CENTER FOR ADDICTION STUDIES AND TREATMENT FOUNDATION | 2016-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10208023-B2 | Heterocyclic inhibitors of the sodium channel | SCN1B, TRPV1, SCN1A | IDO1 751/4885CACNA1H 32/4885KMT2A 2494/4885 |
| US-20160016939-A1 | HETEROCYCLIC INHIBITORS OF THE SODIUM CHANNEL | SCN1B, TRPV1, SCN1A | IDO1 751/4885CACNA1H 32/4885KMT2A 2494/4885 |
| US-20170107203-A1 | HETEROCYCLIC INHIBITORS OF THE SODIUM CHANNEL | SCN1B, SCN1A, CACNA1S | IDO1 1143/4885CACNA1H 20/4885KMT2A 3046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.